Metformin Hydrochloride; Sitagliptin Phosphate

Drug Usage Statistics, United States, 2008 - 2018

Metformin Hydrochloride; Sitagliptin Phosphate Summary for 2018

Estimated number of prescriptions in the United States 3,991,205
Top drug rank #154 ( 15)
Average total drug cost $674.8 (USD)
Average out-of-pocket cost $49.24 (USD)

Number of Prescriptions Over Time (2008 - 2018)

Rank of Top Drugs Over Time

"Rank" refers to the frequency that a given medication is prescribed within a calendar year compared to all other medications. A rank of "4" would indicate that the medication was the fourth most commonly prescribed medication.

Year Rank Change
2008 276  136
2009 240  36
2010 235  5
2011 224  11
2012 207  17
2013 245  38
Year Rank Change
2014 189  56
2015 157  32
2016 191  34
2017 139  52
2018 154  15

Drug Cost Over Time (2008 - 2018)

  • Total cost: The average total cost of the medication including the out-of-pocket cost (see below) plus the amount paid by other parties (Medicare, Medicaid, private insurance, Veterans Administration, TRICARE, other state/federal sources, Worker's compensation, and other miscellaneous sources)
  • Out-of-pocket cost: The average payment made by the patient which may include deductibles, coinsurance, copayments, or the cash price paid without insurance coverage.

Related Drugs

Drug Name Total Prescriptions (2018)
Metformin Hydrochloride 83,762,981
Sitagliptin Phosphate 9,813,528
Metformin Hydrochloride; Sitagliptin Phosphate (this drug) 3,991,205
Linagliptin 3,390,521
Saxagliptin Hydrochloride 1,056,369

Drug Synonyms

Drug synonyms are used during the sanitation and standardization process of "cleaning" the original data source (MEPS). Occassionally, brand names may be listed below that are no longer on the market or are very infrequently used.

Brand Name Synonyms
  • Janumet
  • Janumet XR
Generic Drug Synonyms and Salts
  • Sitagliptin Phosphate; Metformin Hydrochloride
  • Metformin Hydrochloride; Sitagliptin Phosphate

FDA Approval Information

Established Pharmacologic Class (EPC): Biguanide, Dipeptidyl Peptidase 4 Inhibitor
Initial FDA approval date: 3/30/2007
First FDA applicant: Rx
First dosage form: Tablet (oral)

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2008-2018. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 21.1. Read more about the ClinCalc DrugStats database.

All ClinCalc DrugStats figures and graphs on this page are licensed under Creative Commons Attribution-ShareAlike 4.0 International (CC BY-SA 4.0).

Search

Related Links

Follow Us!

New and Popular

Loading...

Open Menu

Cite This Page

Show AMA citation

Easily learn drug therapy with our high-yield videos. The Top 250 Drugs by ClinCalc Academy
 
©2021 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Jan 18, 2021
Back to Top
Top